EOM Pharmaceutical Holdings, Inc.
DelistedCIK 822411fmd_10QGK3PZXD6NW2A01FYGM34C6GManufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2005 to Jun 30, 2018, 38 periods
| Line item | FY2008 | FY2009 | FY2010 | FY2011 | FY2012 | FY2013 | FY2014 | FY2015 | FY2016 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenues | – | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Research and development | – | 1 | 2 | 5 | 8 | 5 | 6 | 11 | 19 | 17 |
| Total operating expenses | – | – | – | – | 12 | 9 | 10 | 16 | 24 | 21 |
| Operating income | – | (3) | (5) | (9) | (12) | (9) | (10) | (16) | (24) | (21) |
| Interest expense | – | – | – | – | – | 0 | 0 | 0 | 1 | 1 |
| Interest and investment income | – | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Income before taxes | – | (3) | (6) | (6) | (14) | (9) | (9) | (13) | (22) | (14) |
| Income tax expense | – | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net income from continuing operations | – | (3) | (6) | (6) | (14) | (9) | (9) | (13) | (22) | (14) |
| Net income | (3) | (3) | (6) | (6) | (14) | (9) | (9) | (13) | (22) | (14) |
| Net income to common shareholders | – | (3) | (8) | (6) | (14) | (9) | – | (13) | (22) | (18) |